Background
The most critical problem facing malaria treatment today is resistance to anti-plasmodial drugs. The emerging resistance of Plasmodium falciparum to the only affordable anti-malarials, chloroquine and sulphadoxine/pyrimethamine, and now even the last effective class of antimalarials, the artemisinins [1, 2] , undermines efforts to eliminate or even manage effectively this deadly disease. Hence, there is continued interest in the discovery of bioactive natural compounds with unique structures that may lead to antimalarial drugs with novel modes of action [3] [4] [5] .
South Africa boasts a rich biodiversity with more than 22,600 indigenous plants, representing about 9% of all higher plants on Earth [6] . There is also a long history of the use of plants in African traditional healthcare systems. This natural resource and indigenous knowledge, together with the historical success of the plant-derived anti-malarials (i.e. quinine, artemisinin) and the universal need for new drugs, prompted a national consortium initiative to discover novel anti-plasmodial agents from South African plants [7] .
One of the plants selected for this study was Dicoma anomala, an erect, suberect or prostrate herb bearing aromatic semi-woody tubers at the base of a woody subterranean stem. This grassland species is widely distributed in sub-Saharan Africa, and is morphologically diverse, resulting in the recognition of several infraspecific taxa. Two subspecies occur in South Africa: D. anomala subsp. anomala and D. anomala subsp. gerrardii [4] .
The numerous ethnomedicinal uses of D. anomala, which range from the treatment of coughs and colds, fevers, ulcers, dermatosis, venereal diseases, labour pains, dysentery, intestinal parasites, stomach pains, toothache and internal worms, can be linked to several pharmacological properties: anti-bacterial, anti-helmintic, anti-viral, anti-plasmodial, anti-spasmodic, wound healing, analgesic and anti-inflammatory [8] [9] [10] [11] . A previous study reported the anti-bacterial and anti-inflammatory properties of the root extracts of D. anomala [9] . Another study demonstrated in vitro anti-cancer activity of extracts of a related species, Dicoma capensis [12, 13] .
Phytochemical investigations of D. anomala have identified several classes of secondary metabolites; including acetylenic compounds, phenolic acids, flavonoids, sesquiterpene lactones, triterpenes and phytosterols [14] [15] [16] . The investigation of a dichloromethane extract of the roots of D. anomala resulted in the isolation of asymmetrical sesquiterpene dimers with potent anti-plasmodial properties [17, 18] . Based on this finding and the reported use of D. anomala in the treatment of fevers, a primary symptom of malaria [8, 9] , an ethyl acetate (EtOAc) extract of the roots of D. anomala subsp. gerrardii was assayed against a chloroquine-sensitive strain of P. falciparum. Its activity warranted further investigation and a sesquiterpene lactone, dehydrobrachylaenolide (Figure 1 ), was isolated by column chromatography and found to show in vitro activity [11] . Structure-activity relationship experiments (through the generation and assessment of simple synthetic analogues) confirmed the requirement for activity as the α-methylene lactone moiety, a feature absent in artemisinin anti-malarials (artesunate, Figure 2 ). The compound was further investigated through transcriptome analysis and comparisons were drawn between the isolated compound and a related sesquiterpene lactone, artesunate (Figure 2 ). Comparative analysis revealed little overlap and confirmed likely different modes of action.
Methods

Plant collection and extraction
Collection of rootstocks of D. anomala subsp. gerrardii was undertaken in the Brits region of the North West Province of South Africa during February 2008. A voucher (BP 01455) was deposited at the National Herbarium of South Africa (Pretoria), and the identity of this taxon confirmed by Dr E. Retief.
A total of 5.6 kg of fresh rootstock was oven dried (30°C) and ground with a hammer mill to yield 3.7 kg of finely processed plant material. Of this, 3.4 kg of the processed material was consecutively extracted with 3 volumes of EtOAc (15 L) at room temperature over 3 days. The filtered extract was concentrated under reduced pressure on a rotary evaporator at 60°C and further dried in a vacuum desiccator for 96 h to remove all traces of solvent. The extraction yielded 48 g of brown gum (1.3% w/w of dry plant material).
Isolation and identification of dehydrobrachylaenolide
Solvent partitioning of the crude extract was used to divide the extract into three fractions with different methylene lactone A B methylene ketone Figure 1 Chemical structure of the sesquiterpene lactone dehydrobrachylaenolide. The potential conjugate acceptor sites (circled in blue) and terminology used in the text of this work are indicated.
polarities. The extract (1 g) was dissolved in 100 mL of aqueous methanol (MeOH/H 2 O 9:1, v/v) and extracted with hexane (3 × 100 mL). MeOH was removed from the aqueous methanolic layer under vacuum on a rotary evaporator; the remaining solution was diluted to 100 mL with H 2 O and extracted with dichloromethane (DCM) (3 × 100 mL). The DCM layers were combined and dried over anhydrous Na 2 SO 4 , filtered and concentrated under vacuum on a rotary evaporator to give a DCM-soluble fraction. This process was scaled up for the remaining crude extract.
Large-scale purification of the DCM-soluble fraction was performed by liquid chromatography in batches of 5 -10 g of extract on 400 -500 g of silica gel 60 (0.063 -0.2 mm) under reduced pressure, using EtOAc/hexane/ DCM/MeOH and acetone/DCM/MeOH gradients. Pooled fractions were combined on the basis of similarity of chemical profile as determined by thin-layer chromatography (TLC). Crude fractions 1A-1L were concentrated under vacuum on the rotary evaporator. Fractions 1D-1H were combined (3.5 g) on the basis of similarity of their TLC profile and subjected to further column chromatography using a 90 cm column packed with silica gel and eluted with an EtOAc/hexane/DCM/MeOH isocratic solvent mixture (9:45:45:1, v/v) to give fractions 2A-2N. The fractions were combined on the basis of similarity of the chemical composition determined by TLC analysis. Further fractionation of 2F (0.4 g) was achieved by means of flash chromatography, using a 40 cm flash column, packed with flash silica gel (silica gel 60) and eluted with a hexane/DCM/EtOAc/MeOH isocratic solvent mixture (45:45:9:1, v/v). This yielded compound 1, which was recrystallized from 2-propanol to yield 400 mg (0.013% w/w of dry plant material) of white orthorhombic crystals.
Compound 1 was identified using standard one-and two-dimensional nuclear magnetic resonance spectroscopic (NMR) experiments; electrospray-ionization mass spectrometry (ESI-MS); X-ray crystallography and by direct comparison with published spectral data [19] [20] [21] .
NMR analysis was carried out on a Varian 400 MHz Unity spectrometer. The mass spectral data were obtained from a hyphenated HPLC-UV/MS instrument (HPLC Waters Alliance 2690 system, equipped with a Waters 996 photodiode array detector and a triple quadrupole Quattro LC Micro mass spectrometer). The mass spectrometer was set to operate in both the ESI -and ESI + modes (49 -478 amu) with a gain of 10; the cone voltage was varied between 20 and 70 eV; the desolvation temperature was 450°C; and the source block temperature was set at 120°C. Crystallography experiments were conducted on an Oxford Diffraction Excalibur-2 CCD area detector diffractometer, using Mo-Kα X-radiation and a graphite-crystal monochromator. Optical rotations were measured in chloroform at room temperature on a Perkin-Elmer 241 polarimeter at 589 nm (Na D-line) using a 1 dm cell.
Parasite cultures
Asexual P. falciparum chloroquine-sensitive 3D7 and D10 cultures, as well as chloroquine-resistant K1 strain cultures, were maintained and synchronized according to established methods [22, 23] in an atmosphere consisting of 5% oxygen, 5% carbon dioxide and 90% nitrogen. The parasites were maintained at a 5% haematocrit in RPMI 1640 medium supplemented with 25 mM HEPES, 22 mM glucose, 0.0088% hypoxanthine, 40 ug/mL gentamycin (all Sigma) and 0.5% Albumax (Invitrogen).
In vitro anti-malarial assay
The anti-plasmodial activities of the extracts and pure compounds were determined against the chloroquinesensitive D10 and the chloroquine-resistant K1 strains via the parasite lactate dehydrogenase (pLDH) assay [24] . All test substances were stored at -20°C prior to testing. Stock solutions of test substances were prepared in 10% MeOH or 10% DMSO (in water), depending on the solubility, and diluted in Millipore water to prepare 2 mg/mL solutions, which were stored at -20°C. Chloroquine diphosphate (Sigma) was used as a reference drug in all experiments. The test substances were evaluated as ten serial two-fold dilutions (0.2 -100 μg/mL final concentration) in medium (two replicates per concentration point) in duplicate wells. The highest concentration of organic solvent that the parasites were exposed to was 0.5%, which was shown to have no measurable effect on parasite viability [7] . Test solutions were mixed with suspensions of infected human red blood cells to achieve a final haematocrit of 1% and parasitaemia of 2% and incubated for 48 h in microtitre plates (250 uL final volume). Incubation conditions were as described above for the routine maintenance of the P. falciparum cultures. The IC 50 values, serving as a measure for anti-plasmodial activities, were calculated by non-linear regression doseresponse analysis using GraphPad Prism v.4.0 software.
In vitro cytotoxicity assay
Compounds were tested for in vitro cytotoxicity against a Chinese hamster ovary (CHO) cell line using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay [25] . The CHO cells were cultured in DMEM: Hams F-12 medium (1:1) supplemented with 10% heat-inactivated foetal calf serum (FCS) and gentamycin (0.04 μg/mL) (Highveld Biological, RSA). Samples were dissolved in 10% MeOH. Stock solutions (2 mg/mL) were prepared and were stored at -20°C until use. The samples were added to CHO cells as five ten-fold serial dilutions ranging from 100 -0.01 μg/mL. A serial dilution of emetine (100 -0.001 μg/mL) was used as a positive control. Cells were seeded in 96-well plates at a concentration of 10 5 /mL (100 μL per well) and incubated at 37°C for 24 h in a humidified 5% CO 2 -air atmosphere. The medium was subsequently aspirated from the wells and replaced with 200 μL of the test compound dilutions. The microplates were incubated at 37°C for 48 h, after which 25 μL of sterile MTT (5 mg/mL in PBS) was added to each well and incubation was continued for 4 h at 37°C. Formazan crystals formed by viable cells were dissolved in DMSO and quantitated by measuring absorbance at 540 nm in a microtitre plate reader (Cambridge Technologies). Cell viabilities were calculated relative to reference wells containing no test compounds (positive cell controls) and no cells (background controls), plotted against log[test sample] and IC 50 values derived by nonlinear regression analysis using GraphPad Prism v.4.0 software.
Generation of synthetic analogues of compound 1
Information on the synthesis of compound 1 analogues for structure-activity relationship studies is provided [see Additional file 1].
Transcriptome analysis
Parasite drug treatment and RNA extraction P. falciparum 3D7 cultures were treated with 12.5 μM of compound 1, corresponding to an inhibitory concentration of IC 99 as determined from dose-response curves. A morphological comparison between compound 1 treated versus untreated parasites was performed to assess the effect of treatment and to establish sampling times, by examining the stage-specific progression of parasites across the intra-erythrocytic development cycle. The solvent (DMSO) or compound 1 was added in the window shortly after red blood cell (RBC) invasion and parasite development was monitored 6 hourly over a 48 h period using conventional Giemsa-stained smears. Fresh cultures were scaled up to 50 ml (5% hematocrit, 10% parasitemia), synchronized twice and treated with compound 1 in the window around invasion. Fifteen milliliters of culture was harvested at each of the stages used for transcriptional analyses (2, 6 and 12 hpt). Similar volumes were harvested from untreated P. falciparum 3D7 control cultures at the same time points. Parallel drug treatments were conducted, serving as biological replicates. RNA was extracted from the frozen erythrocyte pellets as described [26] .
Universal Reference RNA (URR) pool, cDNA synthesis and hybridization
The URR pool was constructed from mixed-stage cultures as described [26] . cDNA synthesis and hybridizations was as described in [26] , with the exception that 40 pmoles of each dye was hybridized to each array, utilising Cy3 (sample) and Cy5 (reference) dyes from GE Healthcare (#RPN5661), specifically optimized for nucleic acid labelling.
Microarray data analysis and real-time quantitative PCR (RT-qPCR)
Generation of GenePix results (gpr) files, LIMMA and MARRAY analysis in the R computing environment, calculation of Pearson correlation coefficients and determination of differentially expressed genes were performed as detailed in [26] . RT-qPCR was performed on an Applied Biosystems 7500 Fast cycler (Carlsbad, California, USA) as described [26] . qPCR primers were designed using Primer3 Plus [27] and sequences are available on request. PCR efficiencies for each sample were calculated using LinRegPCR, software described in [28] . Fluorescence data per cycle of each sample is exported from the Applied Biosystems 7500 Fast cycler, from which the efficiencies of individual samples were calculated. These efficiencies were used to calculate relative expression in a mathematical model described by Pfaffl [29] . Gene ontology analyses were performed using the Micro Array Data Interface for Biological Annotation (MADIBA) software [30] .
Results
Isolation and identification of compound 1
In the search for novel anti-malarials from South African plants, an EtOAc extract of D. anomala subsp. gerrardii was screened against the chloroquine-sensitive D10 strain of P. falciparum using the pLDH assay. The extract exhibited an IC 50 of 1.4 μg/mL [11] .
A phytochemical investigation of this extract resulted in the isolation of a major compound, compound 1. NMR analysis revealed the presence of an a-methylene-g-lactone moiety and two fused cyclohexane rings forming the skeleton of the eudesmanolide-type sesquiterpene lactone. The A ring was found to possess a 1,2-endocyclic double bond, a carbonyl at C-3 and an additional exocyclic methylene at C-4. Compound 1 was subsequently identified as 3-oxoeudesma-1,4(15),11(13)-triene-12,6a-lide, which was identical to the structure of dehydrobrachylaenolide ( Figure 1 , see Additional file 2), previously isolated from Brachylaena transvaalensis [20] , Hieracium intybaceum [31] and various Dicoma species [16] , all of the Asteraceae family. A successful chemical synthesis, which confirmed the structure and absolute configuration of dehydrobrachylaenolide, has been reported [21] .
The relative configuration of the asymmetric centres at C-5, C-6 and C-7 was deduced to be trans based on the size of the observed 1 H NMR coupling constants and NOE correlations. This was in good agreement with previously reported configuration data for dehydrobrachylaenolide [16, 32] , and was subsequently confirmed by X ray crystallography and optical rotation studies [33] .
In vitro anti-plasmodial activity of dehydrobrachylaenolide and its synthetic analogues
The eudesmane-type natural compounds are expected to have various biological activities due to their chemical structure [21] but the anti-malarial activity of dehydrobrachylaenolide has not yet been reported. Sesquiterpene lactones are known to have anti-plasmodial activities [34] [35] [36] [37] and, therefore, the isolated dehydrobrachylaenolide was tested for potential activity against P. falciparum. Toxicity against mammalian CHO cells was used to derive a therapeutic index for the test compound [11] . The results are summarized in Table 1 .
The compound had an IC 50 of 1.865 μM (0.455 μg/mL) against the chloroquine-sensitive D10 strain and 4.095 μM (1.0 μg/mL) against the chloroquine-resistant K1 strain when tested in vitro [see Additional file 3]. Dehydrobrachylaenolide can therefore be considered a hit, because it complies with the basic criteria for anti-parasitic drug discovery [38] with an in vitro IC 50 against whole protozoa of ≤ 1 μg/ml and a selectivity of close to ten-fold more against the chloroquine-sensitive parasites than against the CHO cells (see therapeutic index, Table 1 ).
The working assumption in assessing active functionality was that the levels of unsaturation in the eudesmanolide, in particular the α-methylene lactone within dehydrobrachylaenolide (Figure 1) , would be responsible for the observed activity. Several analogues (2 -6) were synthesized to investigate the structure-activity relationships within dehydrobrachylaenolide and are depicted in Table 2 . Due to the time frames involved in obtaining permits for plant collection, plant collection, and metabolite isolation, a semi-synthetic analogue (2) of dehydrobrachylaenolide (1) was generated by reducing the α-methylene appended to the ketone in the A-ring and increasing the unsaturation of this ring. The synthetic analogue (2) generated lacked the anti-malarial potency of the natural product (1), being six-fold less active against the D10 strain. However, this activity was considered sufficient to examine functional group relationships to activity. Reduction of the α-methylene appended to the lactone yielded santonin (3), which was devoid of any significant anti-malarial activity or mammalian toxicity (as measured by activity against CHO) at the upper concentrations of the biological assays. As expected, complete removal of unsaturation in the A-ring resulted in the generation of a compound (4) lacking both activity and toxicity. Re-introduction of the exocyclic methylene to the lactone resulted in a singly unsaturated derivative (5) which displayed moderate antimalarial activity (about half the potency of the parent (2)). The CHO-based toxicity of this species was, however, substantially reduced (about twenty-fold from the synthetic parent (2) and almost ten-fold from the natural product). The re-introduction of limited unsaturation in the A-ring (6), (tested as a mixture) resulted in no significant improvement in anti-malarial activity with respect to (5), but increased mammalian cell toxicity.
Transcriptome analysis of dehydrobrachylaenolide inhibition Culturing, drug treatment and RNA extraction A morphological analysis was performed with dehydrobrachylaenolide to ascertain the point during intra-erythrocytic development at which P. falciparum 3D7 growth was affected. Drug treatments were performed in the window following RBC invasion (i.e. during the early ring stage growth phase). No significant morphological differences were observed between treated and control cultures immediately following drug administration (T = 0), while at 6 h post-treatment (hpt, T = 6) the majority of the treated parasite cultures were already observed to be developing slower than the untreated cultures ( Figure 3 ). Clear differences in morphological development were visible at 12 hpt (T = 12), where virtually all treated parasites were smaller in size and abnormal in shape compared to the control cultures. Treated parasites remained arrested in the ring phase throughout the rest of the 48-hour intraerythrocytic cycle, by the end of which they were observed to be disintegrated, shrivelled or compact. Based on these morphological observations and the apparent rapid effect of dehydrobrachylaenolide on P. falciparum development, sampling times for transcriptional analysis were subsequently determined as 2, 6 and 12 hpt. RBC Giemsa-stained smears taken at these time points confirmed the onset of the inhibitory effect of dehydrobrachylaenolide within this timeframe.
Gene expression profiling of P. falciparum treated with dehydrobrachylaenolide
A microarray reference design experimental strategy, similar to that described in [26] 4] . A total of 572 unique genes were differentially regulated (cumulatively across all time points) at least two-fold and with a false discovery rate (FDR) cut off of 5% following parasite perturbation with dehydrobrachylaenolide (all genes listed in Additional file 5). The number of differentially regulated genes represents 12.5% of the genes present on the array. Of these, 297 were upregulated (52% of the total), and 275 downregulated (48% of the total). The number of differentially expressed transcripts increased with time following drug addition, as expected from Pearson correlations, which indicates a drug effect on parasite transcription at approximately 6 hpt. Affected transcripts for T 2 , T 6 and T 12 were 134, 291 and 378, respectively. Several transcripts were differentially expressed at more than one time point (e.g. T 2 and T 6 or T 6 and T 12 ). Due to the cytocidal nature of sesquiterpene lactones [39, 40] , the high treatment dose (IC 99 ) and the rapid time of action of dehydrobrachylaenolide, the transcriptional changes observed at the last time point (T = 12) were regarded as less informative concerning mode of action and were not analysed further. In a related transcriptome investigation of P. falciparum parasites treated with lethal doses of artesunate (a derivative of the sesquiterpene lactone artemisinin), time points were harvested after 90 minutes and 3 hours resulting in 398 differentially affected genes [41] . Differentially expressed transcripts were validated by analysing their expression by real-time quantitative PCR (RT-qPCR). The expression of three transcripts (MAL7P1.93 (mitochondrial ribosomal protein S8, putative), MAL7P1.175 (hypothetical protein) and PFL0055 c (protein with DNAJ domain (resa-like), putative)) was evaluated by qPCR, utilising PFL0625 c (eukaryotic translational initiation factor 3) as an endogenous control, as described previously [26] .
There was a good concordance between expression levels from array analysis and those determined by qPCR (Table 3) . At 2 hpt, the expression values (log 2 ) for MAL7P1.93 were 1.09 and 1.29 for array and qPCR analyses respectively, and those for MAL7P1.175 were 1.89 and 2.02. Furthermore, the array expression values for the endogenous control were unchanged (log 2 values at 2 and 6 hpt were 0.0037 and -0.0946, respectively).
MADIBA analyses for metabolic pathways enriched following drug perturbation indicated that several metabolic pathways were involved in the parasite's response to perturbation with dehydrobrachylaenolide. At T 2 , transcripts involved in 20 metabolic pathways were affected; at T 6 , this increased to 26. The only metabolic pathway with an appreciable p-value (in Fisher's contingency test in MADIBA) was "Biosynthesis of type II polyketide backbone", affected at T 6 (p = 0.190). However, there is scant information regarding this pathway in the parasite. Higher p-values are expected from these analyses, since all affected transcripts at a given time point are submitted for analyses, without clustering, as described [26] .
Gene Ontology (GO) analysis for genes affected by dehydrobrachylaenolide treatment, for both Biological Process and Molecular Function, were performed using MADIBA software [30] . Biological Process GO terms occurring at multiple time points (T 2 and T 6 ; at corrected p < 0.05) included chromatin silencing and dephosphorylation. Additional Biological Process GO terms included electron transport and DNA replication (T 2 ) and tRNA modification (T 6 ). The Molecular Function GO term chromatin binding appeared at both T 2 and T 6 ; as did histone binding. In addition, pepsin A activity (T 2 ), actin binding and sugar metabolism (T 6 ) were affected. The GO terms are listed in Table 4 .
Discussion
The EtOAc extract of D. anomala subsp. gerrardii showed sufficient activity against P. falciparum to warrant further investigation. Compound 1, dehydrobrachylaenolide, isolated as a major component of this extract, was subsequently screened for its anti-plasmodial activity and found to exhibit some activity against a chloroquinesensitive D10 strain and a chloroquine-resistant K1 strain of P. falciparum. This is the first report of anti-malarial activity associated with this compound. Dehydrobrachylaenolide was originally isolated from the roots of Brachylaena transvaalensis, from which its name was derived [20] . Several biological activities were reported for this natural product. These included inhibitory activity toward induction of intracellular adhesion molecule-1 (ICAM-1) [21] and anti-bacterial properties [42] . It was also shown to have significant anti-cancer activity in the NCI's 60-cell line panel, with a selectivity trend towards the leukaemia sub-panel [11] .
The activity of dehydrobrachylaenolide against the chloroquine-sensitive strain (IC 50 = 1865 nM) is within an order of magnitude of that of quinine (IC 50 = 194 nM) [43] . Furthermore, against the chloroquine-sensitive strain, the compound has a therapeutic index of 9.2, which is close to the acceptable value of 10 for potential development [38] .
To establish the chemical moieties responsible for the inhibition of P. falciparum inhibition by dehydrobrachylaenolide, synthetic analogues of dehydrobrachylaenolide were tested against P. falciparum utilising the pLDH assay. From these studies, it was concluded that the antimalarial activity was mainly attributable to the conjugate acceptor properties of the methylene lactone and the methylene ketone (in the A-ring, Figure 1 ). The natural product possessed two readily accessible acceptor groups of this type and the absence or inaccessibility of the methylene ketone was responsible for a ten-fold enhancement in activity without concomitant increase in toxicity (or, possibly, a two-fold reduction in toxicity), suggesting that toxic liabilities were largely associated with the methylene lactone. Further examinations relating to the role of A-ring geometry and functionalization could be warranted.
Previously, the authors successfully applied a functional genomics approach to study the effects on the P. falciparum transcriptome of treatment with cytostatic drugs (i.e. DFMO/MDL73811 co-inhibition [44] and cyclohexylamine [26] ). In the study presented here, gene expression profiling was performed on a parasitic cytocidal compound, dehydrobrachylaenolide, subsequent to its isolation, identification, demonstrated anti-malarial activity and structure-activity relationship (SAR) studies. Gene expression profiling of another sesquiterpene lactone, artesunate [41] , reported 398 genes that were differentially expressed compared to untreated P. falciparum parasites. Further to the SAR analyses, comparison [45] . In contrast, the α-methylene-γ-lactone moiety, as well as the conformation of the A-ring (Figure 1 ) of dehydrobrachylaenolide, which is absent in the artemisinins, is significant for various biological activities of the eudesmane sesquiterpene lactones [11, 46] . The structure-activity relationship studies performed for dehydrobrachylaenolide confirmed this.
Conclusions
In this investigation the active constituent of Dicoma anomala subsp. gerrardii was isolated and identified as dehydrobrachylaenolide, an eudesmanolide-type sesquiterpene lactone. The compound demonstrated in vitro anti-malarial activity against a chloroquine-sensitive strain of P. falciparum. Structure-activity relationship studies indicated that exocyclic methylene residues on both the lactone and A-ring appear to be responsible for the observed anti-malarial activity [11] . This methylene lactone moiety is absent in the artemisinin antimalarials, indicating a differentiated mode of action to the artemisinins. Gene expression profiling via microarray strengthened the notion that dehydrobrachylaenolide displays a different mode of action compared to artesunate [41] . In light of the development of resistance against standard anti-malarials (now also including the artemisinins [1, 2] ) and the quest for new drugs with novel modes of action, this finding is significant and underscores the potential of dehydrobrachylaenolide as a potential drug lead. Some recent examples of so-called pro-drugs of sesquiterpene lactones, namely ambrosin, arglabin, parthenin and parthenolide, demonstrate the value of sesquiterpene lactones as lead compounds for the development of pharmaceuticals [47] [48] [49] [50] [51] [52] .
It can be concluded that dehydrobrachylaenolide could play a valuable role as a drug lead. Further mechanistic studies and an in vivo dose response toxicity study would be necessary to gain in-depth knowledge of the structural requirements for selectivity, with respect to the desired biological activity, and systemic toxicity.
Additional material
Additional file 1: Generation of synthetic analogues. The file contains a description of the synthesis of dehydrobrachylaenolide analogues for structure-activity relationship studies. 
